Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

NCT04201873 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

BIOLOGICAL: Dendritic Cell Tumor Cell Lysate Vaccine
BIOLOGICAL: Pembrolizumab
OTHER: Placebo Administration
DRUG: Poly ICLC

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]